Sylvia Kroencke, Christian Wilms, Dieter Broering, Xavier Rogiers, Karl‐Heinz Schulz – 12 July 2006 – While the medical aspects of living donor liver transplantation (LDLT) have been investigated to a comparatively large degree, only in recent years have psychosocial aspects like donors' quality of life and attitude towards living donation been dealt with. In the course of a retrospective study, we examined 36 pediatric living liver donors at an average of 4.5 ± 2.8 years postoperatively.

Gerd Otto, Sascha Herber, Michael Heise, Ansgar W. Lohse, Christian Mönch, Fernando Bittinger, Maria Hoppe‐Lotichius, Marcus Schuchmann, Anja Victor, Michael Pitton – 6 July 2006 – Criteria to select patients with hepatocellular carcinoma (HCC) for liver transplantation (LT) are based on tumor size and number of nodules rather than on tumor biology. The present study was undertaken to assess the role of transarterial chemoembolization (TACE) in selecting patients with tumors suitable for LT.

Jose A. Carrión, Miquel Navasa, Jaume Bosch, Miquel Bruguera, Rosa Gilabert, Xavier Forns – 5 July 2006 – Recurrence of hepatitis C after liver transplantation (LT) is the main cause of graft loss and retransplantation. Frequent liver biopsies are essential to follow‐up hepatitis C virus (HCV)–induced liver damage. However, liver biopsy is an invasive and expensive procedure. We evaluated prospectively the diagnostic accuracy of noninvasive measurement of liver stiffness (by transient elastography) to assess the severity of hepatitis C recurrence after LT.

Michael Kremer, Ian Neil Hines, Richard Jameson Milton, Michael Daryl Wheeler – 23 June 2006 – Steatohepatitis enhances the severity of liver injury caused by acute inflammation. The purpose of this study was to test the hypothesis that fatty liver due to chronic choline‐deficient diet exacerbates concanavalin A (ConA)‐induced liver hepatitis, which is predominantly facilitated by T cells. Male C57BL/6 mice were fed either control choline‐sufficient diet (CSD) or choline‐deficient diet (CDD) for 6 weeks before ConA administration.

Yvonne Meier, Christiane Pauli‐Magnus, Ulrich M. Zanger, Kathrin Klein, Elke Schaeffeler, Andreas K. Nussler, Natascha Nussler, Michel Eichelbaum, Peter J. Meier, Bruno Stieger – 23 June 2006 – Interindividual variability in hepatic canalicular transporter expression might predispose to the development of hepatic disorders such as acquired forms of intrahepatic cholestasis.

Jeffrey Campsen, Richard Hendrickson, Thomas Bak, Michael Wachs, Igal Kam, Russell Nash, Paul Russ, Marilyn Levi – 23 June 2006

Raoul Poupon, Olivier Chazouilleres, Christophe Corpechot, Yves Chrétien – 23 June 2006 – Primary biliary cirrhosis (PBC)–autoimmune hepatitis (AIH) overlap syndrome is a clinical entity characterized by the occurence of both conditions at the same time in the same patient. In addition to PBC‐AIH overlap syndrome, transitions from one autoimmune disease to another have been reported, but no systematic series have been published. We report a series of 12 patients with consecutive occurrence of PBC and AIH (i.e., PBC followed by AIH).

Preeti A. Reshamwala, David E. Kleiner, Theo Heller – 23 June 2006

Javier Vaquero, Mireille Belanger, Andres T. Blei, Roger F. Butterworth – 23 June 2006

Yongke Lu, Arthur I. Cederbaum – 23 June 2006 – The mechanisms by which alcohol causes liver injury are still not certain. Either LPS or CYP2E1 are considered independent risk factors involved in alcoholic liver disease, but mutual relationships or interactions between them are unknown. In the present study, the possible synergistic action of CYP2E1 and LPS in liver injury was investigated by evaluating the effects of pyrazole (inducer of CYP2E1), Chlormethiazole (CMZ), an inhibitor of CYP2E1, and CYP2E1‐knockout mice.